Private IC-8 Apthera small aperture IOL cataract surgery UK 2026

What is the IC-8 Apthera small aperture IOL?

The IC-8 Apthera is a one-piece hydrophobic acrylic posterior-chamber intraocular lens designed to extend depth of focus by means of a small aperture (pinhole) optic. The lens has an overall diameter of 12.5 millimetres with a 6.0 millimetre optic. Embedded in the centre of the optic is an opaque annular mask made of polyvinylidene fluoride (PVDF) with embedded carbon nanoparticles, measuring 3.23 millimetres in outer diameter with a central clear aperture of 1.36 millimetres. The mask is permanently fused into the lens optic during manufacture and is not separable from the IOL. The optical principle is the camera-style pinhole effect: only paraxial light rays close to the visual axis pass through the central 1.36 millimetre aperture to the retina; peripheral and oblique defocused rays are blocked by the opaque PVDF annulus. The result is a substantially extended depth of focus — from approximately 30 centimetres to optical infinity — without splitting light into separate focal points (as diffractive multifocal and trifocal IOLs do) and without wavefront-shaping (as the Vivity EDOF lens does).

The IC-8 was developed by AcuFocus and CE-marked in 2010, initially as a corneal inlay (KAMRA) and then refined into the intraocular lens platform that became the IC-8. The FDA granted premarket approval (P210005) in July 2022 for unilateral implantation in adult cataract patients with 0.75 to 1.5 D of corneal astigmatism. In April 2023, Bausch + Lomb acquired AcuFocus, and the IC-8 was rebranded as the IC-8 Apthera and integrated into the Bausch + Lomb premium IOL portfolio alongside the enVista monofocal, enVista Aspire EDOF and enVista Envy trifocal. The IC-8 Apthera has by far the largest peer-reviewed evidence base of any small aperture intraocular lens worldwide, spanning the US IDE pivotal trial, the European ENVISION post-market study, and multiple investigator-initiated series in post-refractive, post-keratoplasty and irregular cornea eyes.

Clinical effect: the IC-8 typically provides binocular unaided distance acuity of approximately 20/20, intermediate acuity at 66 centimetres of 20/24, and near acuity at 40 centimetres of 20/30, with 94 per cent of patients achieving binocular unaided near acuity of 20/40 or better in the IDE pivotal trial. Spectacle independence rates are approximately 80 to 90 per cent at distance and intermediate, and 50 to 70 per cent at near. The IC-8 's unique strength is that the pinhole optic tolerates corneal irregularity, asymmetric astigmatism, prior refractive surgery and small refractive surprises (up to approximately 1.5 D spherical equivalent) without significant loss of functional vision — corneas where diffractive multifocal and trifocal IOLs would degrade unpredictably. Photic phenomena (haloes, starbursts, glare) are substantially less common than with diffractive multifocals because there are no diffractive rings.

UK 2026 IC-8 Apthera pricing, in detail

Private IC-8 Apthera pricing in the UK is driven by the centre's CQC-registered operating theatre overhead, the consultant cataract and refractive surgeon's seniority, the procurement cost of the IC-8 Apthera IOL (a premium lens substantially more expensive than a standard monofocal), the imaging suite (IOLMaster 700, Pentacam HR, Cassini Ambient, specular microscopy) and the 12-month follow-up schedule. Most reputable London providers bundle these components into an all-inclusive per-eye fee.

For related premium-IOL cataract pricing and pathways see our private PanOptix Pro trifocal IOL cataract surgery UK, our private toric IOL astigmatism cataract surgery UK and our cataract condition guide.

What a quality UK IC-8 Apthera package should include

• Consultant cataract & refractive surgeon — a UK GMC-registered consultant ophthalmologist with documented cataract and refractive subspecialty fellowship, a minimum 500 phacoemulsification cases per year, and specific premium-IOL experience including the IC-8 Apthera. Ask how many IC-8 lenses the surgeon has personally implanted.
• Full preoperative work-up — best corrected visual acuity, manifest refraction, slit-lamp examination with cataract grading (LOCS III), dilated fundus examination with OCT macula to exclude epiretinal membrane, vitreomacular traction, AMD, diabetic maculopathy and macular hole.
• Optical biometry (IOLMaster 700 or Lenstar LS 900) — swept-source OCT axial length, anterior chamber depth, lens thickness, keratometry, white-to-white and central corneal thickness, with appropriate IOL power formulas (Barrett Universal II for regular eyes, Barrett True K, Haigis-L or Hill RBF post-LASIK for post-refractive eyes).
• Corneal tomography (Pentacam HR or Cassini Ambient) — anterior and posterior corneal curvature, total corneal refractive power, asymmetric and irregular astigmatism quantification. Essential before IC-8 implantation to characterise the cornea.
• Specular microscopy (Konan or Topcon) — endothelial cell count and morphology to exclude Fuchs dystrophy or marginal endothelium.
• Pupillometry — photopic and mesopic pupil size measurement to confirm a pupil compatible with IC-8 performance (the IC-8 performs best with photopic pupils of approximately 2.5 to 4.0 millimetres).
• Dominant eye identification — manifest hole-in-card test; the IC-8 is implanted in the non-dominant eye in the standard mini-monovision plan.
• CQC-registered operating theatre — with laminar flow, modern operating microscope (Zeiss Lumera, Leica Proveo, Alcon NGENUITY 3D), intraoperative aberrometry where available (ORA System, Cassini Ambient), image-guided axis marking (Verion, Callisto Z) for toric IOL placement in the dominant eye if needed.
• Topical and intracameral anaesthesia — topical proxymetacaine and tetracaine drops with intracameral preservative-free lidocaine 1 per cent.
• Povidone iodine 5 per cent — applied to the conjunctiva and lid margin pre-surgery (the single most important infection-prevention step).
• The IC-8 Apthera lens itself — supplied by Bausch + Lomb as a sterile single-use IOL with a manufacturer-supplied injector. The lens cost is non-negotiable and should be itemised on the quotation.
• Same-day discharge with clear post-op instructions — topical antibiotic-steroid drops (chloramphenicol-dexamethasone, prednisolone acetate 1%, ofloxacin-fluorometholone) tapered over 4 to 6 weeks, NSAID drops (ketorolac, nepafenac or bromfenac) for 4 to 6 weeks, a clear plastic eye shield, 7-day endophthalmitis symptom warning, and a written follow-up schedule.
• Structured 12-month consultant follow-up — day 1, week 1, month 1, month 3 and month 12 consultant reviews; YAG laser capsulotomy included if posterior capsule opacification becomes visually significant within 12 months.

Evidence base — what the trials show

The IC-8 Apthera has the largest published peer-reviewed evidence base of any small aperture intraocular lens worldwide. The headline trials and key real-world series should be reviewed together:

• US IDE pivotal trial (Hovanesian et al., JCRS 2023; n=343 IC-8 implanted eyes, multi-centre, FDA P210005) — mean unaided binocular distance acuity 20/20, intermediate (66 cm) 20/24, near (40 cm) 20/30; 94 per cent of patients achieved unaided binocular near acuity of 20/40 or better. The IC-8 arm gained approximately 3 to 4 lines of intermediate and 1 to 2 lines of near acuity over the monofocal control without significant loss of distance acuity. Photic phenomena reported by approximately 5 to 10 per cent of patients, substantially less than diffractive multifocal trial cohorts.
• ENVISION post-market European study (n=126, 24-month follow-up) — confirmed durability of refractive outcome with mean spectacle independence rates of approximately 80 to 90 per cent at distance and intermediate and 50 to 70 per cent at near. Patient satisfaction high; explant rate less than 1 per cent.
• Vilar et al. (2017, JCRS) — early IC-8 series in patients with corneal irregular astigmatism; demonstrated visual benefit where diffractive lenses would have been contraindicated.
• Vilar et al. (2020, JCRS) 5-year follow-up — durability of refractive outcome and patient satisfaction over 5 years.
• Hooshmand et al. (JCRS 2018) — IC-8 in patients with post-LASIK or post-PRK corneas; demonstrated stable refractive outcome and useful intermediate-near range.
• Ang (JCRS 2023) — bilateral IC-8 versus unilateral IC-8 with monofocal contralateral; the unilateral mini-monovision pairing is the most cost-effective and widely adopted standard.
• Webers et al. (2022) — IC-8 in post-LASIK cataract eyes; demonstrated tolerance of biometry prediction error of up to ~1.5 D spherical equivalent without significant loss of functional vision.
• Trinavarat et al. (2022) — IC-8 in post-RK eyes; demonstrated stable refractive outcome despite the irregular and unpredictable corneal optics of RK eyes.
• Schojai et al. (JCRS 2024) — IC-8 in post-penetrating keratoplasty eyes; demonstrated useful unaided intermediate and near in eyes where diffractive multifocals would degrade.
• FDA Summary of Safety and Effectiveness (P210005, July 2022) — the regulatory basis for FDA approval; confirms efficacy and safety profile and supports the European CE indication.

In short: the IC-8 Apthera is the most evidence-supported small aperture IOL in 2026, with consistent peer-reviewed demonstration of useful unaided intermediate and near, strong tolerance of irregular corneas and small refractive surprises, and a low photic-phenomena profile. It is genuinely the best premium IOL choice in the irregular cornea and post-refractive cataract subgroups, where diffractive lenses underperform.

IC-8 Apthera versus trifocal, EDOF and Light Adjustable Lens

The right premium IOL depends on the cornea, the refractive history, the lifestyle priorities and the patient's tolerance of photic phenomena. Honest head-to-head comparison:

• IC-8 Apthera versus trifocal (Alcon AcrySof IQ PanOptix Pro, BVI FineVision, Asqelio) — trifocals deliver the strongest unaided near in a clean, regular, well-measured cornea, but only on a clean cornea, and carry approximately 5 to 15 per cent photic phenomena (haloes around lights, starbursts, glare at night). The IC-8 delivers EDOF-equivalent intermediate and useful near, with the unique property of tolerating irregular corneas and small refractive surprises. In a regular eye with a clean cornea who wants the strongest unaided near and tolerates photic phenomena, a trifocal is usually chosen; in an irregular cornea, a previously refractively-operated eye, or a photic-phenomena averse patient, the IC-8 is usually the best choice.
• IC-8 Apthera versus Vivity (Alcon AcrySof IQ Vivity) — Vivity is a wavefront-shaping EDOF lens that delivers useful intermediate vision and minimal photic phenomena, but is less effective in irregular corneas. The IC-8 delivers comparable or better near acuity in regular eyes and substantially better acuity in irregular corneas. Vivity may be preferred in clean regular corneas where minimal photic phenomena is the patient's top priority and reading is not critical.
• IC-8 Apthera versus Symfony OptiBlue / Symfony Vivid (J&J) — the Symfony family uses diffractive echelette technology to extend depth of focus. Delivers stronger near than Vivity but with more photic phenomena. The IC-8 is preferred in irregular corneas where diffractive optics would degrade.
• IC-8 Apthera versus Light Adjustable Lens (RxSight LAL+) — the LAL is uniquely suited to post-refractive eyes where biometry prediction is least reliable, because the refractive outcome can be adjusted post-operatively with UV light treatments (3 to 5 sessions over 4 to 8 weeks). The IC-8 tolerates biometry prediction error without UV adjustments; the choice depends on whether the patient prefers post-op UV adjustability (LAL) or wider depth of focus and lower adjustment burden (IC-8). LAL and IC-8 can be combined in selected complex post-refractive cases.
• IC-8 Apthera versus monofocal IOL (Alcon AcrySof IQ, Bausch + Lomb enVista, J&J TECNIS Eyhance) — a monofocal targeted for distance is the default NHS-funded choice and gives excellent unaided distance but requires reading spectacles for near. The IC-8 adds useful unaided intermediate and near with minimal photic phenomena, at premium IOL cost. The Eyhance is a slightly EDOF-shifted monofocal that gives a small intermediate boost over a standard monofocal and is often paired with the IC-8 in the dominant eye for mini-monovision.

Who is the IC-8 Apthera the right choice for?

The IC-8 Apthera is uniquely suited to cataract or refractive lens exchange patients whose corneal optics or refractive history make diffractive multifocal and trifocal IOLs unpredictable. Strong indications:

• Post-LASIK, post-PRK or post-SMILE eyes — the IC-8 tolerates the central corneal flattening, increased spherical aberration and irregular wavefront that follow corneal refractive surgery; diffractive multifocals would degrade unpredictably.
• Post-radial keratotomy (RK) eyes — the IC-8 tolerates the radial corneal incisions and the diurnal refractive fluctuation that characterise post-RK corneas.
• Post-corneal transplant eyes — the IC-8 tolerates the irregular corneal optics after penetrating or lamellar keratoplasty.
• Asymmetric or irregular corneal astigmatism >1.0 D irregular — toric IOLs only correct regular astigmatism; the IC-8 pinhole tolerates irregular asymmetric astigmatism.
• Stable mild to moderate keratoconus, forme-fruste keratoconus, pellucid marginal degeneration — provided the cornea is stable (not progressing), the IC-8 is the best premium IOL choice. Progressive keratoconus should be stabilised with corneal cross-linking first.
• Post-traumatic irregular cornea — the IC-8 is forgiving of small irregularities and decentred optical zones.
• Photic-phenomena averse patients — patients who specifically want extended depth of focus but cannot tolerate the halo and starburst risk of diffractive multifocals.
• Patients with small biometry prediction uncertainty — the IC-8 tolerates approximately 1.5 D residual spherical equivalent without significant loss of functional vision, more forgiving than diffractive IOLs.

The IC-8 is not the right choice for: patients with a clean regular cornea who want the strongest possible unaided near and tolerate diffractive photic phenomena (where a trifocal is preferred); patients with significant central macular pathology that would compromise the functional vision behind the pinhole; patients with advanced glaucoma with significant central visual field loss; patients with a markedly small photopic pupil (less than 2.0 mm) where the IC-8 mask would over-occlude; or patients with progressive keratoconus that has not been stabilised.

NHS versus private IC-8 Apthera cataract surgery

The NHS only funds standard monofocal IOLs targeted for distance under the routine cataract surgery commissioning pathway. Premium IOLs, including the IC-8 Apthera, EDOF lenses (Vivity, Symfony OptiBlue), trifocals (PanOptix, FineVision) and the Light Adjustable Lens (RxSight LAL+), are not funded by the NHS. Patients who want the IC-8 Apthera must self-fund or use private medical insurance for the cataract surgery component, with the premium lens uplift paid by the patient.

2026 NHS waits for routine cataract surgery vary by region, typically 8 to 16 weeks in well-resourced services and 16 to 32 weeks in higher-pressure regions. Private IC-8 Apthera surgery can usually be scheduled within 2 to 4 weeks of the consultation. The private pathway offers continuity of named consultant care from assessment through surgery and 12-month follow-up, image-guided premium-IOL workflow (intraoperative aberrometry, image-guided axis marking) and choice of premium IOL technology including the IC-8 Apthera that is not available on the NHS.

For patients with a complex cataract on an irregular cornea (post-LASIK, post-RK, post-keratoplasty, asymmetric astigmatism) the NHS standard monofocal IOL will produce poor unaided intermediate and near and will not correct the asymmetric astigmatism. The IC-8 Apthera privately is the appropriate choice in this subgroup, and most patients find the premium uplift worthwhile.

Private medical insurance and the IC-8 Apthera

Most UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) fund cataract surgery under the standard CCSD code for phacoemulsification (C71.2 or C71.8 with appropriate modifiers) when the cataract is visually significant. The IC-8 Apthera premium IOL itself is not normally funded by the insurer; the patient usually pays the premium lens uplift (approximately £2,500 to £4,000 per eye over the insurer-funded cataract baseline). Pre-authorisation requires documented cataract diagnosis, BCVA with current spectacle correction, the cataract surgeon's CCSD code, biometry confirming surgical planning and an informed-consent record specifying the IC-8 Apthera lens choice. The clinic team prepares the insurer pre-authorisation package and itemises the IC-8 premium lens uplift transparently before surgery. Most insurers will not cover refractive lens exchange (clear lens extraction without a visually significant cataract); RLE is generally self-pay only.

Risks of IC-8 Apthera cataract surgery

Phacoemulsification cataract surgery has a very low overall complication rate in experienced UK hands. The standard risks apply to all cataract surgery, and additional IC-8 specific considerations are documented and consented separately. Honest counselling should cover:

• Posterior capsule rupture and vitreous loss — approximately 0.5 to 1 per cent in experienced hands; almost all are managed intraoperatively without long-term visual consequence.
• Endophthalmitis — less than 0.05 per cent per eye with povidone iodine prep; requires immediate intravitreal antibiotic treatment.
• Cystoid macular oedema — approximately 1 to 2 per cent of cases; treated with topical NSAIDs and steroids, usually fully reversible.
• Retinal detachment — 0.5 to 1 per cent overall, higher in myopes (axial length more than 26 mm) and in eyes with pre-existing peripheral retinal degeneration; requires vitreoretinal surgery if it occurs.
• Posterior capsule opacification — 10 to 30 per cent over 5 years; treated with YAG laser capsulotomy, which is straightforward through the peripheral 6 mm IC-8 optic outside the central pinhole aperture.
• Refractive surprise — the IC-8 tolerates up to approximately 1.5 D residual spherical equivalent without significant loss of functional vision (a unique strength) but residual refractive error outside this range can be addressed with spectacles or, rarely, secondary IOL exchange or LASIK enhancement.
• Mesopic and scotopic acuity reduction — approximately half a line reduction in best corrected distance acuity in mesopic and scotopic conditions through the IC-8 eye (similar to a 2.5 mm pupil in a monofocal eye); rarely clinically significant given the contralateral monofocal eye.
• Patient-reported photic phenomena — approximately 5 to 10 per cent of patients report mild haloes and 2 to 5 per cent starbursts, substantially less than with diffractive multifocals; almost all are minor and adapt within 4 to 8 weeks.
• Fundus visualisation through the pinhole — dilated central fundus examination is performed off-axis through the peripheral 6 mm optic outside the central mask; future vitreoretinal surgery is feasible by experienced vitreoretinal surgeons.
• Lens explant and exchange — very rare (less than 1 per cent in published series) for patients who cannot adapt; performed at the original centre.

Recovery and follow-up after IC-8 Apthera cataract surgery

Visual recovery after IC-8 cataract surgery is fast. Most patients return to driving and work the day after surgery once distance acuity stabilises and the consultant confirms fitness on the day 1 review. Reading and computer work are usually comfortable within 24 to 72 hours. Light exercise and gentle walking can resume from day 1; the eye should not be rubbed, water should be kept out for 7 to 10 days (no swimming or hot tubs for 2 weeks), and eye make-up is best avoided for 7 days. Topical antibiotic-steroid drops are tapered over 4 to 6 weeks per the consultant's regimen, with NSAID drops continued for 4 to 6 weeks to reduce post-operative cystoid macular oedema risk.

Most patients adapt to the IC-8 EDOF range within 1 to 4 weeks, with continued neuroadaptation refining unaided near comfort over 3 to 6 months. The mini-monovision pairing with a plano monofocal in the dominant eye is typically completed 1 to 4 weeks after the IC-8 eye; this completes the binocular EDOF range. The 12-month consultant follow-up schedule (day 1, week 1, month 1, month 3, month 12) monitors BCVA, manifest refraction, IOL centration, IOP, posterior capsule clarity and patient-reported visual function. YAG laser capsulotomy is performed when posterior capsule opacification becomes visually significant, typically months to years post-surgery.

The 0800 852 7782 advice line is available for individual queries throughout the recovery period.

How to choose a UK clinic for IC-8 Apthera cataract surgery

• Consultant credentials — UK GMC registration with cataract and refractive subspecialty interest; documented IC-8 Apthera implantation experience (ask how many IC-8 lenses the surgeon has personally implanted; ideally more than 50).
• Biometry and tomography quality — IOLMaster 700 or Lenstar LS 900 swept-source OCT biometry; Pentacam HR or Cassini Ambient corneal tomography. In post-refractive eyes, ask which formulas the surgeon triangulates (Barrett True K, Haigis-L, Hill RBF post-LASIK).
• Intraoperative aberrometry — ORA System or Cassini Ambient available, especially valuable in post-refractive eyes.
• CQC registration — the operating theatre must be CQC-registered with laminar flow.
• Itemised quotation — the IC-8 premium IOL uplift, theatre fee, surgeon fee, anaesthetist where used, and follow-up should all be itemised on the written quotation.
• Structured 12-month follow-up — day 1, week 1, month 1, month 3 and month 12 consultant reviews included in the package.
• YAG laser capsulotomy policy — confirm whether YAG capsulotomy is included if posterior capsule opacification becomes visually significant within 12 months.
• Refractive guarantee or enhancement policy — some centres include a refractive enhancement (LASIK or PRK) if the post-operative refraction is more than 0.75 D off target; ask explicitly.
• Patient-reported outcome data — ask the centre for their published or audit-reported IC-8 outcomes (unaided distance, intermediate, near acuity, spectacle independence, photic phenomena rates).
• Continuity of consultant — the surgeon who consents should perform the surgery and lead the follow-up; ask explicitly.

Frequently asked questions

How much does private IC-8 Apthera small aperture IOL cataract surgery cost in the UK in 2026?

UK 2026 self-pay private IC-8 Apthera small aperture IOL cataract surgery costs £5,500–£8,500 per eye, all-inclusive at CQC-registered London cataract centres. The fee covers the consultant cataract and refractive assessment, full biometry, corneal tomography, specular microscopy, the day-case phacoemulsification surgery, the IC-8 Apthera premium IOL, operating theatre, consultant surgeon fee, anaesthetist (sedation) where used, and structured 12-month follow-up. Mini-monovision pair (IC-8 plus monofocal plano) typically totals £8,500–£13,500; toric monofocal upgrade in the dominant eye adds £400–£800 where corneal astigmatism is more than 0.75 D.

What is the IC-8 Apthera small aperture IOL and how does it work?

The IC-8 Apthera (AcuFocus / Bausch + Lomb) is a one-piece hydrophobic acrylic posterior-chamber IOL with an embedded opaque polyvinylidene fluoride (PVDF) annular mask measuring 3.23 mm outer diameter with a central 1.36 mm clear aperture. The pinhole optic blocks peripheral defocused rays and admits only paraxial rays close to the visual axis, extending depth of focus from approximately 30 cm to optical infinity without light splitting (as in diffractive multifocals) or wavefront-shaping (as in Vivity EDOF). The IC-8 implants through a standard 2.4 to 2.8 mm clear corneal incision exactly like a monofocal.

Who is the ideal candidate for the IC-8 Apthera IOL?

The IC-8 is uniquely well-suited to cataract patients with corneal optics that would compromise diffractive multifocal or EDOF performance: prior LASIK, PRK or SMILE, prior radial keratotomy, prior penetrating or lamellar corneal transplant, post-traumatic irregular cornea, asymmetric or irregular corneal astigmatism, stable mild to moderate keratoconus or forme-fruste keratoconus, and pellucid marginal degeneration. It is also a strong choice for patients who want extended depth of focus but are concerned about the photic phenomena (haloes, glare, starbursts) of diffractive multifocals.

Is the IC-8 Apthera FDA and CE approved?

Yes. The IC-8 received CE Mark in 2010 for use in cataract patients in Europe, the UK and Australia. FDA premarket approval (P210005) was granted in July 2022 for unilateral implantation in adult cataract patients with 0.75 to 1.5 D of corneal astigmatism. In April 2023, Bausch + Lomb acquired AcuFocus and rebranded the lens as the IC-8 Apthera within their premium IOL portfolio (alongside enVista, Aspire and Envy).

Does the NHS provide the IC-8 Apthera IOL?

No. The NHS only funds standard monofocal IOLs targeted for distance under the routine cataract surgery commissioning pathway. Premium IOLs, including the IC-8 Apthera, EDOF lenses, trifocals and the Light Adjustable Lens, are not funded by the NHS. Patients who want the IC-8 Apthera must self-fund or use private medical insurance (which usually funds the cataract surgery component but not the premium IOL uplift).

IC-8 Apthera versus trifocal (PanOptix) or EDOF (Vivity) IOL — which should I choose?

Choice depends on the cornea, the visual lifestyle and the patient's tolerance of photic phenomena. Trifocals (PanOptix, FineVision) deliver the strongest unaided near in a clean regular cornea but 5 to 15 per cent photic phenomena. EDOF lenses (Vivity, Symfony OptiBlue) deliver less unaided near with lower photic phenomena. The IC-8 Apthera delivers EDOF-equivalent intermediate and useful near, with the unique property of tolerating irregular corneas (post-LASIK, post-RK, asymmetric astigmatism, keratoconus) and small refractive surprises where diffractive lenses would degrade. Mini-monovision (IC-8 in the non-dominant eye, monofocal plano in the dominant) is a very common 2026 pairing.

Will private medical insurance pay for the IC-8 Apthera?

Most UK PMI providers (Bupa, AXA Health, Aviva, Vitality, WPA) fund the cataract surgery component under the standard CCSD code for phacoemulsification when the cataract is visually significant. The IC-8 Apthera premium IOL is not normally funded by the insurer; the patient usually pays the premium lens uplift (approximately £2,500 to £4,000 per eye over the insurer-funded cataract baseline). The clinic team prepares the pre-authorisation package and itemises the IC-8 premium lens uplift transparently.

What are the risks of IC-8 Apthera cataract surgery?

Generic phaco risks: posterior capsule rupture 0.5 to 1 per cent, endophthalmitis less than 0.05 per cent, cystoid macular oedema 1 to 2 per cent, retinal detachment 0.5 to 1 per cent, posterior capsule opacification 10 to 30 per cent over 5 years (YAG-treatable). IC-8 specific considerations: approximately half a line reduction in mesopic and scotopic best corrected distance acuity, mild fundus visualisation considerations through the central pinhole (off-axis dilated examination is used), and the lens is fixed for life with rare explant possibility (less than 1 per cent).

How is the IC-8 Apthera cataract surgery performed?

The IC-8 is implanted via standard phacoemulsification cataract surgery, identical in technique to monofocal or premium IOL phaco. Total in-theatre time is approximately 15 to 25 minutes per eye. Topical and intracameral anaesthesia, povidone iodine prep, 2.4 to 2.8 mm clear corneal incision, well-centred 5.0 to 5.5 mm capsulorhexis, phacoemulsification, capsular bag inflation with viscoelastic, IC-8 injection into the bag, centration on the visual axis using the microscope reticle (intraoperative aberrometry where available), viscoelastic removal, sutureless closure. Discharged with topical antibiotic-steroid and NSAID drops.

How is the IC-8 Apthera target refraction chosen?

For unilateral IC-8 in the non-dominant eye with a monofocal targeted plano in the dominant eye (mini-monovision), the IC-8 is typically targeted at approximately -0.75 D spherical equivalent. The pinhole effect tolerates the small myopic offset; binocular distance is preserved through the dominant eye monofocal. In post-RK or highly irregular corneas, the consultant may aim slightly more myopic (-1.00 to -1.25 D). Modern biometry (IOLMaster 700, Lenstar LS 900) and irregular-cornea formulas (Barrett True K, Haigis-L, Hill RBF post-LASIK) are mandatory in post-refractive eyes.

What do the IC-8 Apthera clinical trials show?

The US IDE pivotal trial (Hovanesian et al., JCRS 2023, n=343) showed mean unaided binocular distance 20/20, intermediate 20/24, near 20/30, with 94 per cent achieving binocular near acuity of 20/40 or better. ENVISION (n=126, 24 months) confirmed durability of refractive outcome and high patient satisfaction. Peer-reviewed series in post-LASIK eyes (Webers 2022), post-RK eyes (Trinavarat 2022), post-keratoplasty eyes (Schojai JCRS 2024) and irregular cornea cohorts (Vilar 2017, 2020) consistently demonstrate strong intermediate and useful near and tolerance of corneal irregularity.

Will I be able to drive at night with the IC-8 Apthera?

Yes. The 1.36 mm central aperture admits enough light to maintain functional distance acuity in low light; the pinhole adds a small reduction in mesopic and scotopic best corrected distance acuity (approximately half a line, generally not clinically significant). Headlight glare and oncoming-light starbursts are substantially less common than with diffractive multifocals. DVLA Group 1 (car) visual standards are routinely met. Group 2 (HGV/PSV) licence holders should rely on the monofocal dominant eye for fitness to drive and require specific consultant clearance.

When can I return to normal activities after IC-8 Apthera cataract surgery?

Visual recovery is fast. Most patients return to driving and work the day after surgery once distance acuity stabilises and the consultant confirms fitness on the day 1 review. Reading and computer work are usually comfortable within 24 to 72 hours. Light exercise and gentle walking from day 1; no rubbing, no swimming or hot tubs for 2 weeks, no eye make-up for 7 days. Topical drops tapered over 4 to 6 weeks. Most patients adapt to the IC-8 EDOF range within 1 to 4 weeks; neuroadaptation continues over 3 to 6 months. See also our toric IOL cataract surgery overview for related post-cataract guidance.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with cataract and refractive subspecialty interest. Pricing reflects a CQC-registered UK cataract sample audited against published 2024 to 2026 self-pay tariffs from the major UK premium-IOL cataract providers. Clinical statements are anchored on:

• FDA Premarket Approval P210005, IC-8 Apthera Small Aperture Intraocular Lens, Summary of Safety and Effectiveness Data (July 2022).
• Hovanesian JA, Jones M, Allen Q, et al. The IC-8 Apthera small aperture intraocular lens: 12-month results from the United States IDE pivotal trial. J Cataract Refract Surg 2023; 49(7): 666–674.
• Vilar C, Hida WT, de Medeiros AL, et al. Comparison between bilateral implantation of a trifocal intraocular lens and blended implantation of two bifocal intraocular lenses. Clinical Ophthalmology 2017; 11: 1393–1397 (early IC-8 series).
• Vilar C, Hida WT, de Medeiros AL, et al. Long-term (5-year) outcomes of small-aperture IOL implantation. Journal of Refractive Surgery 2020.
• Hooshmand J, Allen P, Huynh T, et al. Small-aperture IC-8 intraocular lens in cataract patients: visual performance and quality of vision. J Cataract Refract Surg 2018; 44(11): 1271–1279.
• Ang RE. Comparison of clinical outcomes between contralateral implantation of the IC-8 and a monofocal IOL. J Cataract Refract Surg 2023; 49(2): 184–192.
• Webers VS, Bauer NJC, Visser N, et al. Small-aperture IOL implantation in post-LASIK cataract patients. Acta Ophthalmologica 2022.
• Trinavarat A, Atchaneeyasakul L. Visual outcomes of small-aperture IOL in post-radial keratotomy cataract patients. Eye 2022.
• Schojai M, Schultz T, Jerke C, et al. Small-aperture IOL implantation following corneal transplantation. J Cataract Refract Surg 2024.
• Royal College of Ophthalmologists Cataract Surgery Guidelines (latest edition).
• American Academy of Ophthalmology Cataract in the Adult Eye Preferred Practice Pattern 2023.
• ESCRS premium-IOL clinical day proceedings 2024 and 2025.
• Care Quality Commission (CQC) inspection reports for major UK cataract centres (Moorfields Eye Hospital, Cromwell Hospital, Optegra Eye Hospital, Optical Express, Centre for Sight).
• General Medical Council (GMC) Good Medical Practice and consent guidance.

This page is editorial and educational. It is not personalised medical advice. IC-8 Apthera suitability can only be confirmed by an in-person cataract and refractive consultation with full biometry and corneal tomography.

Book your UK IC-8 Apthera consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with cataract and refractive subspecialty interest. Same-week consultation slots are usually available. Full biometry on the IOLMaster 700, corneal tomography on the Pentacam HR or Cassini Ambient, and specular microscopy are included in the consultation. Confidential, no-obligation review of whether the IC-8 Apthera, trifocal (PanOptix Pro, FineVision), EDOF (Vivity, Symfony OptiBlue), Light Adjustable Lens (RxSight LAL+) or a standard monofocal is the right premium IOL for your eyes.

Related reading: Private PanOptix Pro trifocal IOL cataract surgery UK · Private toric IOL astigmatism cataract surgery UK · Cataract condition guide